<DOC>
	<DOCNO>NCT01244620</DOCNO>
	<brief_summary>Sitaxsentan low drug-drug interaction potential clinically relevant effect pharmacokinetics sildenafil ( CYP3A sensitive substrate PDE5 inhibitor ) . Tadalafil clinically relevant effect pharmacokinetics bosentan ambrisentan . Based overall clinical drug-drug interaction profile , vitro CYP enzymes transporter data , clinically relevant drug-drug interaction sitaxsentan tadalafil expect . Sildenafil expect affect sitaxsentan pharmacokinetics ( PK ) , sitaxsentan substrate CYP3A4 CYP2C9 , sildenafil show clinically relevant effect PK substrates CYP3A4 CYP2C9 .</brief_summary>
	<brief_title>A Pharmacokinetic Drug-Drug Interaction ( DDI ) Study Between Sitaxsentan And Sildenafil , And Between Sitaxsentan And Tadalafil After Multiple Doses</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Healthy male subject woman nonchild bear potential age 21 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . An informed consent document sign date subject legally acceptable representative . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) clinical finding Screening . A positive urine drug screen . Subjects hepatic dysfunction , define aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal range Screening . A retest may do AST and/or ALT within 1.5 2 time upper limit normal range Screening , average first repeated test value use decide eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>A pharmacokinetic drug-drug interaction study sitaxsentan tadalafil sitaxsentan sildenafil steady-state</keyword>
</DOC>